Neil Klompas's most recent trade in InMed Pharmaceuticals Inc was a trade of 1,750 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| InMed Pharma Inc | Neil A. Klompas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2025 | 1,750 | 5,250 | - | - | Employee Stock Option (Right to Buy) | |
| InMed Pharma Inc | Neil A. Klompas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Oct 2025 | 3,500 | 3,500 | - | - | Employee Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Neil Klompas | President & COO | Sale of securities on an exchange or to another person at price $ 7.83 per share. | 10 Mar 2023 | 2,977 | 17,032 (0%) | 0% | 7.8 | 23,298 | Common Stock |
| Zymeworks BC Inc | Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,708 | 20,009 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,708 | 2,709 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,500 | 17,301 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,500 | 0 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Neil Klompas | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 87,500 | 87,500 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Neil Klompas | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 58,500 | 58,500 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Neil Klompas | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 4.51 per share. | 05 Jul 2022 | 1,525 | 14,801 (0%) | 0% | 4.5 | 6,878 | Common Shares |
| Zymeworks BC Inc | Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 29.49 per share. | 06 Jul 2021 | 299 | 10,770 (0%) | 0% | 29.5 | 8,818 | Common Shares |
| Zymeworks BC Inc | Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 8,125 | 8,125 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 11,896 (0%) | 0% | 0 | Common Shares | |
| Zymeworks BC Inc | Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 5,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Neil Klompas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.95 per share. | 10 Mar 2021 | 1,425 | 10,471 (0%) | 0% | 35.0 | 49,809 | Common Shares |